FDA Clearance Tracker · P160045
Oncomine Dx Target Test
Last checked: Nov 19, 2026Latest source record: Jun 22, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jun 22, 2017
Approved
Time to decision
248 days
Received Oct 17, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160045
- Device name
- Oncomine Dx Target Test
- Applicant
- Life Technologies Corporation
- Applicant location
- Carlsbad, CA
- Received
- Oct 17, 2016
- Decided
- Jun 22, 2017
- Decision
- Approved
- Supplements
- 44 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the The Oncomine Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high throughput, parallel-sequencing technology to detect single nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from patients with non-small cell lung cancer (NSCLC) using the Ion PGM Dx System. The test is indicated to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling.Table 1. List of variants for therapeutic useGene Variant Targeted therapyBRAF BRAF V600E TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib)ROS1 ROS1 fusions XALKORI® (crizotinib)EGFR L858R, Exon 19 deletions IRESSA® (gefitinib)Safe and effective use has not been established for selecting therapies using this device for the variants in Table 1 in tissue types other than NSCLC.Results other than those listed in Table 1 are indicated for use only in patients who have already been considered for all appropriate therapies (including those listed in Table 1). Analytical performance using NSCLC specimens has been established for the variants listed in Table 2.Table 2. List of variants with established analytical performance onlyGene Variant ID Nucleotide changeKRAS COSM512 c.34_35delGGinsTTKRAS COSM516 c.34G>TMET COSM707 c.3029C>TPIK3CA COSM754 c.1035T>AThe test is not indicated to be used for standalone diagnostic purposes, screening, monitoring, risk assessment, or prognosis.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PQP. The earliest in FDA's data is P160018, decided Dec 19, 2016.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Life Technologies Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260827 · Decided Oct 15, 2026 · 216 days after receipt
Device type: High Throughput Sequencing Based Tumor Profiling Test Of Circulating Cell-Free Nucleic Acids (SBY) · Laboratory Medicine & Pathology
- Oncomine Dx Express TestPMA supplement
P240040-S005 · Decided Sep 9, 2026 · 180 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
P240040 · Decided Jul 2, 2025 · 232 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.